| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10964634 | Vaccine | 2015 | 10 Pages |
Abstract
The clinically acceptable safety and immunogenicity profile of M72/AS01E in adolescents living in an area with high TB burden support the move to efficacy trials.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Adam Penn-Nicholson, Hennie Geldenhuys, Wivine Burny, Robbert van der Most, Cheryl L. Day, Erik Jongert, Philippe Moris, Mark Hatherill, Opokua Ofori-Anyinam, Willem Hanekom, the Vaccine Study Team the Vaccine Study Team, Anne Bollaerts,